PYPD - PolyPid's oncoplex cancer program shows encouraging action in animal study

PolyPid ([[PYPD]] +9.9%) has reported preclinical data from its OncoPLEX intra-tumoral cancer therapy program, demonstrating single local treatment showed improved overall survival and significantly less tumor recurrence when compared to multiple injections with standard systemic Chemotherapy colon cancer animal models.OncoPLEX utilizes the Company’s PLEX technology designed for the delivery of sustained, significant concentrations of docetaxel, one of the most widely used chemotherapy agents, in the intra-operative tumor resection setting.OncoPLEX arm showed 25% overall tumor recurrence at the end of the study (day 39 post-surgery) compared to 75% in the systemic treatment arm, and 100% in the untreated control arm. Tumor free survival was 75% vs. 25% vs. 0% and overall survival was observed at 75% vs. 50% vs. 0%.On the safety front, systemic toxicity was lower following application of OncoPLEX versus systemic docetaxel. Additional data showed that the maximal plasma concentration of docetaxel was >10 times lower with OncoPLEX than with

For further details see:

PolyPid's oncoplex cancer program shows encouraging action in animal study